Acromegaly Update

Ethan Weiss
  • 0,0 (0)
  • Levenswetenschappen
  • Wekelijks bijgewerkt

Weekly digest of new research on acromegaly — trials, therapies, and clinical updates.

  1. 2 dgn geleden

    Acromegaly Update — Monday July 13, 2026

    It was a quiet week for new acromegaly research, but the rare disease industry delivered its biggest story of the year — Vertex's $10 billion acquisition of Crinetics Pharmaceuticals, maker of the acromegaly drug Palsonify, directly linking this week's two segments.

  2. 6 jul

    Acromegaly Update — Monday July 6, 2026

    It's a thin week for acromegaly-specific research — just one mechanistic study on tumor biology — but rare disease dealmaking was busy, headlined by Ipsen's ~$800M bet on a kidney-transplant antiviral and an FDA age expansion for Vertex's CRISPR therapy Casgevy.

  3. 29 jun

    Acromegaly Update — Monday June 29, 2026

    Paltusotine's four-year open-label data confirm durable oral control of acromegaly in patients switched from injections, while the rare disease industry absorbs a landmark Sangamo bankruptcy, a well-funded gene-editing entrant in AATD, and a new build-to-buy cardiomyopathy venture from Merck KGaA.

  4. 22 jun

    Acromegaly Update — Monday June 22, 2026

    A rich week in acromegaly research — new data on renal complications, a precision medicine framework, a high-risk co-secreting tumor phenotype, and cancer risk analyses — while the rare disease industry continues to see a wave of FDA regulatory reversals benefiting gene therapy developers.

  5. 15 jun

    Acromegaly Update — Monday June 15, 2026

    Surgical technique innovation and a JCEM editorial from two giants of the field reshape how we think about curing GH-secreting tumors and managing cancer risk in acromegaly, while the rare disease sector sees a burst of late-stage deal-making and platform financing that signals strong investor conviction in gene-silencing technologies.

  6. 8 jun

    Acromegaly Update — Monday June 8, 2026

    A landmark JCEM special issue lands this week with five major reviews and original studies that collectively reset the clinical playbook for acromegaly — from emerging oral therapies to the underappreciated mortality burden — while in the rare disease industry, Alnylam bets $2 billion on AI-designed RNA medicines, a controversial FDA voucher program faces calls for reform, and a new market forecast projects orphan drug sales above $400 billion by 2032.

  7. 1 jun

    Acromegaly Update — Monday June 1, 2026

    New Pituitary research this week highlights the cardiac and bone risks that persist even in treated acromegaly patients, while the rare disease industry grapples with a mixed regulatory environment — one notable ASCO data release and continued fallout from FDA leadership turnover.

  8. 25 mei

    Acromegaly Update — Monday May 25, 2026

    A network meta-analysis confirms that injectable somatostatin receptor ligands remain first-line in acromegaly, while new clinical data on paltusotine and pasireotide, plus rare disease industry news including BioMarin and Intellia, shape the week.

Bekijk alles (13)

Info

Weekly digest of new research on acromegaly — trials, therapies, and clinical updates.

Informatie

  • Maker
    Ethan Weiss
  • Jaren actief
    2026
  • Afleveringen
    13
  • Beoordeling
    Veilig
  • Copyright
    © Ethan Weiss / Marea Therapeutics
  • Website van aflevering
    Acromegaly Update